GlassScriptPhysician profile
Mylissa Persons
NPI 1992132328
$7,083.17
in general payments reported to CMS, 2019-2025
34 companies · $1,732 in 2025
The $1,732 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $377 · 2022: $1,620 · 2023: $1,711 · 2024: $1,644 · 2025: $1,732.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,021 · Education: $65.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,020.84 |
| Education | $65.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,119.11 | 2021-2025 | |
| Novo Nordisk INC | $1,014.84 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $681.36 | 2021-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Esperion Therapeutics, INC. | $630.61 | 2021-2025 | Nexletol |
| Pfizer INC. | $552.08 | 2022-2025 | |
| Lilly USA, LLC | $475.02 | 2022-2025 | Jardiance, Mounjaro, Emgality |
| Amgen INC. | $438.83 | 2021-2025 | Evenity, Otezla, Repatha |
| Boston Scientific Corporation | $290.39 | 2023-2024 | Watchman Flx |
| Astellas Pharma US INC | $270.10 | 2023-2025 | Veozah, Myrbetriq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $242.79 | 2021-2023 | Synjardy, Jardiance |
| Ibsa Pharma INC. | $156.05 | 2021-2025 | Licart, Tirosint, Flector |
| Biohaven Pharmaceutical Holding Company LTD. | $139.17 | 2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $135.29 | 2025 | Caplyta |
| Janssen Pharmaceuticals, INC | $126.58 | 2022-2024 | Xarelto |
| Astrazeneca Pharmaceuticals LP | $84.22 | 2022-2024 | Farxiga |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $83.94 | 2021-2024 | Freestyle Libre 3 |
| Xeris Pharmaceuticals, INC. | $78.35 | 2022-2024 | Keveyis |
| Sanofi-Aventis U.S. LLC | $75.68 | 2024-2025 | |
| Exact Sciences Corporation | $55.89 | 2024-2025 | Cologuard Collection Kit |
| Grt US Holding, INC. | $52.03 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $50.48 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $49.79 | 2022-2025 | Capvaxive, Gardasil 9, Gardasil |
| Aimmune Therapeutics, INC. | $45.29 | 2024-2025 | Zenpep |
| Philips North America LLC | $34.91 | 2023 | |
| Sunovion Pharmaceuticals INC. | $33.64 | 2021-2022 | |
| Novartis Pharmaceuticals Corporation | $29.12 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $20.72 | 2023 | Cuvitru |
| Axsome Therapeutics, INC. | $20.45 | 2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $20.14 | 2024 | Givlaari |
| Halozyme INC | $18.38 | 2023 | |
| Sanofi Pasteur INC. | $17.17 | 2023 | |
| Antares Pharma, INC. | $15.92 | 2022 | |
| Nestle Healthcare Nutrition INC. | $13.06 | 2022 | |
| Jazz Pharmaceuticals INC. | $11.77 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mylissa Persons listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.